Last edition
News about "Multiple myeloma treatment"
Sanofi Secures Japan Approval for Subcutaneous Formulation of Sarclisa
Sanofi’s Sarclisa subcutaneous formulation has been approved in Japan for patients with multiple myeloma. The approval is supported by the Phase 3 IRAKLIA study and marks the second global approval after the EU.
Multiple Myeloma Treatment | 22/06/2026 | By News Bureau
Venus Remedies Secures Saudi FDA Approval for Plerixafor Oncology Therapy
Venus Remedies receives Saudi FDA approval for Plerixafor, marking its first global marketing authorisation for the specialty oncology therapy used in stem cell mobilisation for multiple myeloma and non-Hodgkin lymphoma patients undergoing autologous transplantation.
Multiple Myeloma Treatment | 25/05/2026 | By News Bureau | 144
TDB-DST Backs Helix Cell Therapeutics for CAR-T Therapy against Multiple Myeloma
Technology Development Board (TDB) supports Helix Cell Therapeutics and Biocell Innovations in developing dual-targeting CAR-T cell therapy for multiple myeloma under an Indo-Singapore collaboration.
Multiple Myeloma Treatment | 14/05/2026 | By News Bureau | 131
Gilead Sciences Completes Arcellx Inc. Acquisition Ahead of Anito-cel Launch
Under the terms of the transaction, Gilead acquired Arcellx for USD 115 per share in cash, plus one non?transferable Contingent Value Right (CVR) of USD 5 per share, representing a total implied equity value of approximately USD 7.8 billion at the time of closing.
Multiple Myeloma Treatment | 29/04/2026 | By News Bureau | 131
US Food and Drug Administration Extends Review Timeline for Sarclisa Subcutaneous Formulation
FDA extends review timeline for Sanofi’s Sarclisa subcutaneous formulation, a potential first-in-class on-body injector therapy for multiple myeloma patients.
Multiple Myeloma Treatment | 23/04/2026 | By News Bureau | 210
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy